Introduction
Vesicoureteral reflux (VUR) is the retrograde flow of urine from urinary bladder to upper urinary tract. VUR is graded I-V depending on the degree of dilatation and renal collecting system morphology [1] . VUR is the most common congenital urological abnormality of urinary tract occurring in 1 % of newborns [2] . For children with antenatal hydronephrosis on prenatal ultrasound, up to 20 % may be diagnosed with VUR [3, 4] . Like other congenital anomalies of the kidney and urinary tract, VUR has a strong genetic component. VUR occurs in 27.4 % of siblings of affected children and in 35.7 % of the children of affected parents [5] . Thirty to forty percent of children investigated for UTI have VUR [6] . With recurrent UTI, children with VUR are at risk for renal scarring that ultimately can result in chronic or end-stage renal disease. In 2006, in the USA alone, costs exceeded $100 million for hospitalizations related to VUR [7] .
VUR came into focus after the advent of voiding cystourethrography (VCUG) in 1950. Hodson and Edward showed the relationship of VUR with chronic pyelonephritis [8] . Historically, VUR was treated almost exclusively by open surgical reimp l a n t a t i o n o f t h e u r e t e r a l s o k n o w n a s ureteroneocystostomy (UNC). With the recognition that VUR often resolves spontaneously with time, the concept of continuous antibiotic prophylaxis (CAP) was introduced to prevent UTI while waiting for VUR resolution. The identification of bowel and bladder dysfunction (BBD) as a related risk factor for UTI and VUR outcomes has prompted a greater focus on co-managing these functional disorders. Additionally, advances in technology have improved minimally invasive surgical approaches for treating VUR.
Currently, a large academic discussion has focused on the utility of antibiotic prophylaxis in children with VUR. The 2011 AAP technical report reviewed eight clinical trials in a meta-analysis and questioned the utility of CAP. This report found no difference in placebo group and antibiotic prophylaxis group in the rate of recurrent pyelonephritis, regardless of reflux grade and age [9] . However, a significant difference in the rate of UTI in prophylactic group was noted when all forms of UTI were included.
Recently, two large randomized studies were published that demonstrated the benefit of CAP in preventing UTIs in children with VUR. The Rand o m i z e d I n t e r v e n t i o n f o r C h i l d r e n w i t h Vesicoureteral Reflux (RIVUR) study, a large multicenter, randomized placebo-controlled trial, involving 607 children between the ages of 2 to 71 months with grade I to grade IV reflux, showed that prophylaxis reduced the risk of recurrence of UTI by almost 50 % (95 % CI, 0.34 to 0.74) [10••] . Another large, multicenter clinical trial in Sweden that involved 203 children aged 1 to younger than 2 years with grade III to IV reflux also showed a reduction in recurrent UTIs in girls on CAP [11••] . Both studies indicate a role for CAP, especially in young girls, in preventing UTI occurrence.
Another global academic debate has focused on when to screen for VUR. Depending on the context and availability of imaging modalities, a clear, evidenced-based consensus cannot be reached on when to screen children for VUR. Furthermore, similar ambiguity exists with when to screen children of parents with VUR and siblings of children with VUR [5] . The discussion of the approach to the patient with possible VUR is outside the scope of this review.
Education
Parents of children with VUR often have misconceptions about the nature of VUR and UTIs [12] . Parents should be educated about the pathophysiology of VUR, signs and symptoms of UTI, and the indications and methods for collecting urine for culture. This time spent educating families may aid appropriate detection and treatment of UTIs and decrease chronic untreated UTIs and false diagnoses. Many symptoms may be falsely attributed to VUR or UTI and consequently may lead to detection bias. For example, bacteriuria is often noted in inappropriately collected urine samples (such as bagged urine) and labeled by parents and practitioners as a BUTI.^Confirming the diagnosis of a UTI requires both symptoms and a positive urine culture. Typical symptoms of UTI include dysuria, urinary frequency, urgency, or hematuria. Atypical symptoms may include fever, malaise, abdominal or flank pain, diarrhea, vomiting, and weight loss. Malodorous urine is often cited by parents as a symptom of UTI when in fact the association is weak [13] . Unexplained fever in the child with VUR should prompt a workup for a urinary source if no other cause is readily apparent. Proper urine collection for culture often requires catheterization in young children who are unable to cooperate adequately for clean catch collection. Screening via urinalysis of bagged urine sample may be appropriate only when followed by confirmatory catheterized sample collection and culture.
Pharmacologic treatment
Pharmacological treatment of VUR aims at prevention of recurrent UTI. Current evidence suggests that CAP reduces the rate of recurrent UTI until the reflux resolves. The majority of lower grade VUR spontaneously resolves as the child grows [14] . CAP consists of prescribing daily antibiotics at one quarter to one half the normal therapeutic dose. Trimethoprim-sulfamethoxazole (TMP-SMX), amoxicillin, and nitrofurantoin are the most commonly used CAP agents. The significant drawback to CAP is antibiotic resistance. The RIVUR trial demonstrated a significant amount of resistance to TMP-SMX in patients on prophylaxis with breakthrough UTI compared to patients on placebo [10••] .
Trimethoprim-sulfamethoxazole
Mechanism of action: TMP-SMX combination acts to inhibit the formation of bacterial tetrahydrofolate which is required for protein synthesis. Sulfonamides are structurally similar to para-aminobenzoic acid (PABA) used by bacteria for synthesis of folic acid [15] . Sulfamethoxazole (sulfonamide) inhibits the enzyme dihydropteroate synthetase and the formation of dihydropteroic acid, which converts to dihydrofolic acid. Trimethoprim inhibits the enzyme dihydrofolate reductase which is required for conversion of dihydrofolate to tetrahydrofolic acid [16] .
Standard dosage: Standard prophylactic dose of TMP-SMX is based on TMP dose of 2 mg/kg/day in children ≥2 months. The maximum single dose was 160 mg TMP/dose. Dose adjustment is required for patients with chronic kidney disease.
Contraindications: TMP-SMX is contraindicated in neonates/infants younger than 2 months and patients with a history of hypersensitivity to any component of TMP-SMX, Steven-Johnson syndrome, G6PD and pyruvate kinase deficiencies, liver disease, pregnancy, prolonged QT interval, and porphyria [17] .
Main drug interactions: Warfarin, cyclosporine, phenytoin sodium, cyclosporine, angiotensin-converting enzyme inhibitors and receptor blockers, and hypoglycemic urticarial agents.
Main side effects: Nausea, vomiting, loss of appetite, rash, pruritus, and urticaria. Skin-related side effects are more common with TMP-SMX combination compared to sulfonamides alone (5.9 vs. 1.7). Serious, but rare, side effects include StevenJohnson syndrome, toxic epidermal necrolysis, and agranulocytosis ∼0.1 % for sulfonamides) [16] .
Special points: Patients with G6PD deficiency may develop hemolysis. Cost/cost effectiveness: TMP-SMX is an inexpensive medicine.
Amoxicillin
Mechanism of action: Amoxicillin is a broad-spectrum, second-generation, beta-lactam penicillin. Like other penicillins, amoxicillin inhibits the enzymes involved in bacterial cell wall synthesis, inhibiting the formation of peptidoglycan linkages, with activity against Gram-negative organisms [18] . Enzymes involved in bacterial cell wall synthesis are detected by radioactively labeled penicillins and are called penicillin-binding proteins. Amoxicillin penetrates the porin channels of Gram-negative bacteria but is still susceptible to betalactamase enzyme. Recently, the role of murein hydrolase enzyme activity is also shown to play the role in mechanism of action of penicillins [19] . Standard dosage: Amoxicillin is given orally at 10-15 mg/kg/dose (preferably in the evening) for prophylaxis of VUR in infants ≤2 months. Maximum single dose, 500 mg.
Contraindications: Hypersensitivity to amoxicillin, penicillins or other betalactams.
Main drug interactions: Penicillins increase the anticoagulant effect of vitamin K antagonist, increase the serum levels of methotrexate, and interfere with typhoid vaccine.
Main side effects: Rash (91 %) and diarrhea (91 %) are the most common side effects. Rarely, dental discoloration and candidiasis can occur. Serious side effects such as anaphylactoid reactions are rare (0.004-0.04 %) [20] .
Special points: Patients with infectious mononucleosis can develop rash while taking amoxicillin.
Cost/cost-effectiveness: Amoxicillin is an inexpensive medicine.
Nitrofurantoin
Mechanism of action: Nitrofurantoin is converted by bacterial nitroreductase (flavoproteins) into active intermediates that inactivate bacterial ribosomal proteins and halt protein synthesis in bacteria including DNA and RNA [21] . Nitrofurantoin is bactericidal at therapeutic doses. Standard dosage for UTI prophylaxis: 1-2 mg/kg as a single daily dose; maximum dose, 100 mg/day.
Contraindications: Nitrofurantoin is contraindicated in patients with GFR less than 60 ml/h, anuria, oliguria, history of cholestatic jaundice, hypersensitivity to drug and its components, and children less than 1 month of age.
Main drug interactions: Nitrofurantoin interacts with norfloxacin, nitric oxide, spironolactone, and magnesium trisilicate.
Main side effects: Gastrointestinal side effects (4.4 %) such as abdominal discomfort, nausea, and vomiting are most common. Skin rashes and urticaria are also common (3.2 %). Pulmonary complications (0.7 %) such as chest pain or interstitial pneumonitis may also rarely occur. Serious side effects like hepatotoxicity, neurotoxicity, and hematological reactions are extremely rare [22] .
Special points: Nitrofurantoin is not indicated for the treatment of pyelonephritis. Drug absorption is better if taken with meal and can cause brown discoloration of urine. Cost/cost effectiveness: Nitrofurantoin is an inexpensive medicine.
Surgery
The aim of surgical management is to prevent VUR by elongating the intramural tunnel of the ureter or altering the shape or angle of the ureteral orifice to allow coaptation during bladder filling. Open surgical ureteroneocystostomy (UNC) continues to be the gold standard for correction of VUR. Hutch was the first to report surgical correction in seven out of nine paraplegic patients with VUR in 1952 [23] . Over the past 60 years, multiple surgical techniques, including endoscopic and laparoscopic techniques, have been described.
Open ureteroneocystostomy
Open ureteroneocystostomy (UNC) is considered the gold standard in treatment due to its high surgical success rate and low complication rate. Long-term success of open UNC to correct VUR is 98 % [24•]. The surgery is classified by its approach to the ureter as intravesical, extravesical, or combined. Well-established surgical principles to ensure a good clinical outcome include the following: recognition, treatment and resolution of secondary causes of VUR, adequate mobilization of the ureter without tension or damage to its blood supply, creation of a submucosal tunnel that has at least a 5:1 ratio of length to ureteral lumen, and good detrusor muscle backing within the tunnel to create an antireflux mechanism via compression of the ureter during bladder filling and emptying. Recent studies have concentrated on reducing morbidity by improving preoperative and postoperative care, refinement of postoperative analgesia, reducing the size of the incision, and minimizing catheter usage [25] . Complication rates for UNC remain low, and the most commonly reported complications include urinary tract infection, persistent VUR, contralateral de novo VUR, and obstruction. Contralateral VUR after unilateral UNC is reported to be 5.6-18 % with a trend towards development of contralateral VUR in patients with high-grade (grade 4-5) ipsilateral VUR [26, 27] . Prophylactic bilateral UNC for unilateral VUR is not universally recommended due to high spontaneous resolution rates of the de novo contralateral VUR [28] .
Minimally invasive ureteroneocystostomy
Recently, both laparoscopic and robotic assisted laparoscopic ureteroneocystostomy (LUNC/RALUNC) have been introduced as viable surgical treatment options for VUR. Both intravesical and extravesical techniques have been described which follow the same surgical principles of open surgery. Reported success and complication rates are similar to that of open UNC, 89-97.6 % [29, 30] . In a recent retrospective study comparing open UNC (39 patients) and RALUNC (39 patients), no significant difference was found in pain but significantly longer operative times for both intravesical and extravesical RALUNC. The study also noted shorter hospital course and transurethral catheter duration associated with intravesical RALUNC compared to open UNC. Both clinical and radiologic success rates were found to be similar [31] . Another key challenge with EI treatment is reproducibility of the results. Several techniques have been described to help improve surgical outcomes. In the original subureteric Teflon injection method (STING), the injection needle is inserted 2-3 mm distal to the ureteral orifice and advanced 4-5 mm submucosally prior to injection. The goal is to form a crest in the distal submucosal tunnel leading to coaptation of the ureter. Within the last decade, recent EI modifications have improved clinical outcomes. The hydrodistention-implantation technique (HIT) and double HIT methods have demonstrated a significant improvement in resolution rate after 1 year of follow-up [33, 34] . Multiple retrospective review articles have noted that despite the introduction of endoscopic Dx/HA injection for VUR, the rate of UNC has remained stable. Since 2002, the average number of EI antireflux surgeries performed per institution has decreased likely secondary to concerns over the long-term efficacy and cost-effectiveness of EI as a viable treatment option [35, 36] .
Endoscopic injection

Bowel and bladder dysfunction
Bowel and bladder dysfunction (BBD) is a relatively new term which replaces the previously used dysfunction elimination syndrome (DES) [37] . BBD is an umbrella term which encompasses functional disorders of bowel and lower urinary tract (LUT), the full taxonomy of which are out of the scope of this article. Briefly, BBD is divided into bowel dysfunction (e.g., constipation, encopresis, etc.) and LUT dysfunction (e.g., urgency, frequency, enuresis, etc.).
Association between vesicoureteral reflux and BBD
Bowel and bladder dysfunction is clearly associated with VUR, UTIs, and the outcomes of treatment for VUR. The largest analysis of VUR and BBD was performed by the American Urological Association (AUA) guideline committee and was published in 2010 [38••] . Pooled metaanalysis of 16 study arms of 2039 children with VUR showed that 32 % had concurrent BBD. In the meta-analysis of patients on CAP, including patients with high and low grade reflux, BBD was associated with 31 % rate of spontaneous VUR resolution. In comparison, 61 % of patients without BBD had resolution of reflux. Additionally, breakthrough UTIs in children on CAP occurred in 44 % of children with BBD as compared to only 13 % of patients without BBD.
Febrile or symptomatic UTI can occur even after surgical treatment of VUR and is increased in patients with BBD. In the AUA meta-analysis, 22.6 % of children who had surgery for VUR had a subsequent UTI if they had BBD [38••] . UTI incidence was only 4.8 % after successful surgery in children without BBD. Failure of EI for VUR has been classically associated with BBD; however, recent reports have shown that patients with active BBD who are undergoing active treatment (urotherapy) can have satisfactory outcomes equivalent to those without BBD [39, 40] . Persistence of VUR after UNC is rare. In a retrospective review of 400 patients who underwent UNC at our institution, all 11 children with persistent VUR after surgery had significant BBD [41] .
Evaluation of BBD
Evaluation of children with VUR and suspected BBD should start with a careful and detailed history to document symptoms including incontinence (frequency, timing, and volume), voiding frequency, voiding urgency, voided volumes, fluid intake, and frequency and quality of bowel movements. Details about maladaptive behaviors and signs should also be collected, such as voiding postponement, posture during voiding, wiping patterns for female patients, post-void dribbling, straining with defecation, etc. History of specific behaviors should be elicited such as the Bpotty dance^or BVincent curtsy^wherein a female child will squat and press the heel of the foot against the perineum. This sign is classically associated with BBD, specifically voiding postponement and overactive bladder. The use of bowel/bladder diaries and validated questionnaires such as the dysfunctional voiding symptom score (DVSS) have been shown to increase specificity in diagnosing BBD and can be used to document improvement after intervention [42] . The Bristol stool chart is another simple metric which can improve accuracy of parent reported stool quality. Noninvasive uroflowmetry, post-void residual (PVR) measurement, and pelvic floor electromyography (EMG) are useful adjuncts typically performed in the urologist's office and can help distinguish between the various subcategories of LUT dysfunction. Invasive testing such as urodynamics is rarely indicated in the workup of BBD in neurologically intact children.
Urotherapy
Behavioral modification is the frontline treatment for BBD and is often termed Use of a programmable watch which gives an audible or vibrating reminder to facilitate timed voiding has been shown to increase compliance with urotherapy as well as decrease incontinence episodes though it was only studied on children older than 5 years of age [43] . A recent pilot study was also published about the efficacy of group visits for urotherapy which have been proposed to improve compliance and decrease the costs of care. The study was focused on older children (95 years of age) with BBD and showed significant improvement in LUT symptoms in children receiving either individual or group therapy sessions [44] .
Pelvic floor biofeedback
In addition to standard urotherapy, many practitioners have reported success from an additional regimen of pelvic floor muscle (PFM) physical therapy using biofeedback. Protocols vary but typically consist of a series of visits in which the child is instructed on PFM contraction and relaxation. This is often facilitated by a visual/animated computer program that gives feedback using EMG signals from leads placed on the perineum. Some studies have documented benefits from biofeedback in uroflowmetry patterns, post-void residuals, and in rates of UTI [45, 46] .
However, the largest meta-analysis of biofeedback for LUT dysfunction was published recently and found no significant difference in rates of UTI, resolution of incontinence, or maximum urinary flow rate as compared to standard urotherapy [47] .
Bowel management
Bowel dysfunction and bladder dysfunction are clearly linked with multiple proposed mechanisms explaining the relationship [48•] . Parents often focus on urinary symptoms and may not notice or report bowel symptoms without prompting. The first step in treatment is to educate parents and children about proper bowel habits and function. Constipation is very common and may require disimpaction followed by prevention through dietary modification and/or daily osmotic stool softeners such as polyethylene glycol [48•] . Some have advocated treating all children with LUT dysfunction for constipation based on the very high rate of coincident constipation among these patients, the unreliability of parent reporting of bowel symptoms, and the low cost and risk associated with this treatment [49] . However, a recent randomized trial comparing polyethylene glycol versus placebo for patients with isolated bladder urgency symptoms found no difference in resolution of bladder symptoms between the two groups [50] . Bowel dysfunction should be identified, quantified using objective metrics, and treated appropriately. However, all patients with VUR and LUT dysfunction may not benefit from blanket treatment.
Emerging therapies
With rising concerns of antimicrobial resistance and almost zero new antibiotics in the development pipeline, new therapies and approaches to patients with VUR are desperately needed. No longer can we take a Bone size fits all^approach to children with VUR. Studies to elucidate the genetic and host factors that lead to recurrent UTI and renal scarring risks are desperately needed. In the modern day world of precision medicine, each patient will need a UTI recurrence/scarring risk score to establish what therapy (CAP, UNC, observation, EI, etc.) conveys the most benefit with the least amount of risk.
Conclusion
Vesicoureteral reflux continues to be a significant source of pediatric morbidity. Though not all patients with VUR will develop UTIs and most will not suffer renal injury, it is difficult to predict outcomes in advance for each patient. BBD is clearly associated with outcomes of VUR and should be managed appropriately. Surgical and pharmacologic management remain important approaches to reduce the morbidity and expense of UTIs as well as potentially decrease risk of renal injury and insufficiency. Future research may allow individual risk stratification and allow targeted intervention for patients at the highest risk.
